IMR Press / EJGO / Volume 26 / Issue 4 / pii/2005187

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma

Show Less
1 Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Cancer Research Center, Ben-Gurion University of the Negev, Beer-Sheva (Israel)
Eur. J. Gynaecol. Oncol. 2005, 26(4), 386–390;
Published: 10 August 2005
Abstract

Purpose of investigation: To report the experience of a single institution in the south of Israel with weekly carboplatin in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma. Methods: The hospital records of ten patient、 with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma who had 2nd-line or later chemotherapy with weekly carboplatin between January 2003 and December 2004 were retrospectively reviewed. Weekly carboplatin, at a dose calculated with use of the Hilary Calvert's formula at AUC = 2, was given intravenously in 500 ml dextrose 5% over 30 minutes on day 1 of every seven days. Response was determined using clinical evaluation, radiologi­cal reports and CA-125 level. Toxicity was graded using the National Cancer Institute (NCI) criteria. Results: Overall, 155 courses of weekly carboplatin were given. The median number of courses per patient was 14 (range, 2-37) and median duration of treatment was 22.5 (range, 2-40) weeks. Four patients (40%) had complete response lasting for 8-20 (median, 12) weeks, two (20%) had partial response lasting for five and 14 weeks, respectively, one (10%) had stable disease lasting for 23 weeks and three (30%) had progressive disease. Toxicity was mainly hematological with only grade 1-2 hematological toxicity as follows: anemia - four patients (40%), leukopenia - three (30%), neutropenia - three (30%) and thrombocytopenia - two (20%). Conclusion: Weekly carboplatin has considerable activity and low and well tolerated toxicity in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.

Keywords
Ovarian carcinoma
Chemotherapy
Carboplatin
Disease response
Toxicity
Share
Back to top